BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Becton, Dickinson and Company (BDX) Announces Appointment of Dr. Ellen Strahlman as Chief Medical Officer and Senior Vice President, Research & Development


3/13/2013 7:18:43 AM

FRANKLIN LAKES, N.J., March 13, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Ellen Strahlman, M.D., M.H.Sc., to the newly created position of Chief Medical Officer and Senior Vice President, Research & Development, effective April 22, 2013. Dr. Strahlman will report to Chairman, CEO and President Vincent A. Forlenza and will serve as a member of the Company's Management Committee and Leadership Team. In her new role, Dr. Strahlman will oversee the Company's Medical Affairs and Research & Development functions.

"I am very pleased that Dr. Strahlman will be joining BD at a time when we are strategically focused on driving growth through innovation and customer focus," said Mr. Forlenza. "She brings extensive experience as a senior physician and leader in the pharmaceutical and medical device industries, and her patient-centric approach aligns with our focus on providing innovative solutions to address the healthcare needs of customers and patients."

Dr. Strahlman joins BD from GlaxoSmithKline, where she served as Senior Vice President and Chief Medical Officer since 2008 and more recently worked in the Office of the CEO as Senior Medical Advisor and Global Head of Neglected Tropical Diseases. As GSK's Chief Medical Officer, Dr. Strahlman had accountability for safety and patient matters for all programs in development and commercialized products in the Vaccines, Pharmaceutical and Consumer businesses, as well as organizational responsibility for medical affairs, regulatory affairs, clinical safety and other areas. Prior to GlaxoSmithKline, Dr. Strahlman has held executive leadership roles at Merck, Novartis, Pfizer, and Bausch & Lomb that included oversight of the development and commercialization of proprietary and generic pharmaceuticals, drug delivery systems and medical devices.

Dr. Strahlman obtained her M.D. from the Johns Hopkins University School of Medicine, her M.H.Sc. from the Johns Hopkins School of Public Health and her B.A. degree from Harvard University.

About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contacts:
Colleen T. White, Corporate Communications 201-847-5369
Colleen_white@bd.com
Monique N. Dolecki, Investor Relations 201-847-5378
Monique_dolecki@bd.com

SOURCE BD (Becton, Dickinson and Company)



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES